
As a young surgical resident at Presbyterian University Hospital in 1987, “the clock didn’t matter” at the busiest transplant center in the world, led by Thomas E. Starzl, Tim Billiar recently recalled.
“There was an entourage following Dr. Starzl around the hospital at 2 a.m. any night of the week,” said Billiar, now the executive vice president and chief scientific officer for UPMC and chair of the department of surgery.
Visiting physicians, surgeons and scientists from all over the world came to the hospital to learn from the man who had performed the world’s first liver transplant in Denver in 1963 and launched the nation’s first liver transplant program for adults and children in Pittsburgh in 1981.
“Dr. Starzl was held in high reverence for the time he gave to other doctors who wanted to learn from him,” said Billiar. “He always gave them time.”
There were also Monday night lab meetings that would “go on for hours.”
“It’s very unusual to have a lab meeting on a Monday night, but if you were a Starzl disciple, you were there, and Dr. Starzl was the master of ceremonies,” said Billiar. “He listened to others during those meetings, but he also asked a lot of questions and gave direction. His mind was always going. Like many geniuses, he couldn’t turn it off.”
Read More
Starzl served as the chief of transplantation services at Presbyterian University Hospital (now UPMC Presbyterian), Children’s Hospital of Pittsburgh (now UPMC Children’s Hospital of Pittsburgh) and the Veterans Administration Hospital in Pittsburgh (now VA Pittsburgh Health Care) from 1981-91. During that time, he and his team at the University of Pittsburgh Transplantation Institute transformed the practice of liver transplantation from experimental to routine. The institute, renamed the Thomas E. Starzl Transplantation Institute in 1996, performed 30 liver transplants its first year. That number grew to 600 liver transplants performed in one year by 1987.
“Dr. Starzl innovated on so many fronts but focused on the liver because people were dying from liver disease,” said Billiar. “At that time, end-stage liver disease was essentially a death sentence.”
Nearly a decade after Starzl’s death, his legacy continues, through the institute he helped build, those he mentored and the research — particularly, in the realm of anti-rejection drugs — he championed to push transplantation forward.

While Starzl performed surgeries and directed the institute, he also continued to study organ rejection. One of the biggest challenges of organ transplantation is preventing the patient’s immune system from attacking the donor organ. Before 1989, this was achieved through an immunosuppressive drug, cyclosporine. In 1989, Starzl and colleague John Fung developed a new immunosuppressant treatment called tacrolimus, or FK506, which was much more powerful than cyclosporine and with fewer side effects.
During his clinical rotation at Presbyterian University Hospital in 1989, one of George Mazariegos’ on-call duties was to administer the first doses of FK506 to patients. Mazariegos returned to Pittsburgh for a critical care medicine fellowship in 1991 and joined the transplant institute in 1994. He now serves as chief of pediatric transplantation at UPMC Children’s Hospital of Pittsburgh.
“I feel very honored to be the only remaining active surgeon at UPMC who worked with Dr. Starzl,” said Mazariegos.

Although Starzl retired from clinical practice in 1991, he continued to lead significant research at the institute until his death, at age 90, in 2017. It was during those later years that Mazariegos got to know him on a “more personal level.”
“Truth-telling was very important to Dr. Starzl,” said Mazariegos. “If I didn’t know something, it was OK for me to say that. Lying would have broken a fundamental rule.”
This commitment to truth and transparency led Mazariegos and his colleagues to establish the Starzl Network for Excellence in Pediatric Transplantation, which is a community of pediatric transplant centers across the country that shares data and technology.
“The purpose of the Starzl Network is to improve patient outcomes and increase the pace of change in transplant medicine by collaborating instead of competing,” said Mazariegos.

Starzl never took any steps to protect the intellectual property that he was developing. His goal was to educate a generation of physicians that could further develop the field of transplantation.
“It’s impossible to measure the global impact that Dr. Starzl’s mentorship had on the physicians, surgeons and scientists who interacted with him,” said Mazariegos.

Angus Thomson, distinguished professor of surgery and immunology at the University of Pittsburgh, worked with Starzl in the early 1990s as a visiting professor of surgery. He and Mazariegos collaborated on early studies of transplant patients who were able to tolerate their donor organ without immunosuppressive drugs — research that was important to Starzl.
“Immunosuppressive drugs are a two-edged sword,” said Thomson. “They’re very effective in preventing rejection of the transplanted organ, but, over time, patients who are on immunosuppressants are at an increased risk of infectious diseases, they have an increased chance of developing certain types of cancers and injuring their kidneys, etc.”
Thomson’s research, referred to as cell therapy, focuses on reducing or removing a patient’s dependency on immunosuppressants by manipulating certain types of white blood cells that can signal to the immune system to accept the donor organ instead of attacking it.
“We’re encouraged that a small proportion of participants in our trials have remained off immunosuppression,” he said.

The clinical testing of Thomson’s cell therapy approach has been done in collaboration with Abhinav Humar, clinical director of the Starzl Transplantation Institute and chief of UPMC Transplant Services. Humar recruits patients to the trial, follows their progress and determines whether they can remain off immunosuppressive drugs.
Having known Starzl only after he retired from clinical practice, Humar noted he “knew a very different Dr. Starzl,” who felt more like a family member than a colleague.
Starzl, he recalled, believed transplantation is a field of medicine where you always have to push the boundaries.
“Dr. Starzl opened the book on transplantation and wrote many of the chapters, but there are more chapters left to write,” said Humar. “He serves as an example to all of us about how to be so focused in your life on something you feel passionately about that you can achieve the impossible.”
Beth Vassallo (eliz.vassallo@gmail.com) is a freelance writer based in Morningside.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.